title: Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer.
abstract: OBJECTIVE
  Trastuzumab is known to be effective for early and advanced stages of breast cancer but optimal duration for early-stage breast cancer (EBC) is not well known. We evaluated the efficacy and toxicity of 9- and 52-week trastuzumab therapy for EBC retrospectively.
  
  
  METHODS
  In this multicenter study, the medical records of all patients with EBC were analyzed in 8 centers retrospectively. Totally consecutive, 479 female patients who received trastuzumab in the adjuvant treatment were evaluated for disease-free survival (DFS), overall survival (OS), efficacy, and toxicity.
  
  
  RESULTS
  There were 181 (37.8 %) and 298 (62.2 %) patients in the 9- and 52-week trastuzumab groups, respectively. Median follow-up was 30.6 months (5.7-68.9) in the 9-week trastuzumab group and 29.3 months (5.9-59.6) in the 52-week trastuzumab group. Thirty-six month DFS was 90 and 85 % (P = 0.132) in the 9- and 52-week trastuzumab treatment groups, respectively, and 36-month OS was 96 and 97 % in the 9- and 52-week trastuzumab groups, respectively (P = 0.779). Symptomatic cardiotoxicity was observed in 1 (0.6 %) patient in the 9-week trastuzumab group and in 4 (1.3 %) patients in the 52-week trastuzumab group.
  
  
  CONCLUSIONS
  In this study, similar outcomes were found in the 9- and 52-week trastuzumab treatment groups.
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Gazi University, 06500, Besevler, Cankaya, Ankara, Turkey. tonyalionder@yahoo.com
authors.forename: Onder
authors.initials: O
authors.lastname: Tonyali
authors.forename: Ugur
authors.initials: U
authors.lastname: Coskun
authors.forename: Nur
authors.initials: N
authors.lastname: Sener
authors.forename: Mevlude
authors.initials: M
authors.lastname: Inanc
authors.forename: Tulay
authors.initials: T
authors.lastname: Akman
authors.forename: Berna
authors.initials: B
authors.lastname: Oksuzoglu
authors.forename: Nuriye Yildirim
authors.initials: NY
authors.lastname: Ozdemir
authors.forename: Dogan
authors.initials: D
authors.lastname: Yazilitas
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
authors.forename: Aytug
authors.initials: A
authors.lastname: Uner
authors.forename: Deniz
authors.initials: D
authors.lastname: Yamac
authors.forename: Umut
authors.initials: U
authors.lastname: Demirci
authors.forename: Ramazan
authors.initials: R
authors.lastname: Yildiz
authors.forename: Halit
authors.initials: H
authors.lastname: Karaca
authors.forename: Olcun Umit
authors.initials: OU
authors.lastname: Unal
authors.forename: Oznur
authors.initials: O
authors.lastname: Bal
authors.forename: Mahmut
authors.initials: M
authors.lastname: Gumus
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000379:methods; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D012189:Retrospective Studies; D000068878:Trastuzumab; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab